Log in

Relevant bibliographies by topics / Non-Hodgkin's lymphoma (NHL) / Journal articles

To see the other types of publications on this topic, follow the link: Non-Hodgkin's lymphoma (NHL).

Journal articles on the topic 'Non-Hodgkin's lymphoma (NHL)'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Non-Hodgkin's lymphoma (NHL).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nogai, Hendrik, Bernd Dörken, and Georg Lenz. "Pathogenesis of Non-Hodgkin's Lymphoma." Journal of Clinical Oncology 29, no. 14 (2011): 1803–11. http://dx.doi.org/10.1200/jco.2010.33.3252.

Full text

Abstract:

The understanding of the molecular pathogenesis of non-Hodgkin's lymphomas (NHL) has significantly improved in recent years. Advances in molecular biology and genetics lead to the identification and characterization of several oncogenic pathways involved in lymphomagenesis. This knowledge will ultimately lead to improved diagnostic and therapeutic strategies for patients with NHL. This review summarizes current concepts of the molecular pathogenesis of the most common NHL subtypes, with a special emphasis on diffuse large B-cell lymphoma, the most common lymphoma subtype.

APA, Harvard, Vancouver, ISO, and other styles

2

Nitrean, Adrian, and Vasile Musteata. "EPIDEMIOLOGICAL, MEDICO-SOCIAL FEATURES AND TREATMENT OF AGGRESSIVE NON-HODGKIN'S LYMPHO." Deutsche internationale Zeitschrift für zeitgenössische Wissenschaft 54 (April 19, 2023): 40–45. https://doi.org/10.5281/zenodo.7845465.

Full text

Abstract:

Introduction: Aggressive non-Hodgkin's lymphoma (NHL) is the most common malignant neoplasm of lymphoid tissue , which often affects the elderly [1]. In 2019, aggressive NHL in patients aged 65 years and older accounted for about a quarter of the estimated 74,000 new cases of NHL in the US [1,2]. Up to two-thirds of patients have peripheral lymphadenopathy. Skin rash, hypersensitivity reactions to insect bites, general fatigue, itching, malaise, fever of unknown origin, ascites, and effusions are uncommon [1]. The standard treatments for aggressive NHL are R-CHOP chemotherapy and other che

APA, Harvard, Vancouver, ISO, and other styles

3

Akhter, A., MR Rahman, N. Majid, et al. "Histological Subtypes of Non-Hodgkin's Lymphoma in Different Age and Sex Groups." Bangladesh Medical Journal 41, no. 1 (2014): 32–36. http://dx.doi.org/10.3329/bmj.v41i1.18779.

Full text

Abstract:

Non Hodgkin's lymphomas (NHL) constitute a heterogeneous group of neoplasm of the lymphoid system. There are many histological subtype of NHL based on WHO classification of haemotopoietic and lymphoid neoplasm. This cross-sectional study was carried out in the department of Pathology, Dhaka Medical College, Dhaka from January 2009 to December 2010 to observe the different subtypes of NHL in different age and sex groups. A total of 50 microscopically diagnosed case of NHL irrespective of age and sex were included in the study. The diagnostic morphologic criteria of each lymphoma subcategory wer

APA, Harvard, Vancouver, ISO, and other styles

4

Blick, C., S. Abdelhadi, D. Bailey, and A. Muneer. "Anaplastic, T-Cell, Non-Hodgkin's Lymphoma Presenting with Haematuria." Scientific World JOURNAL 8 (2008): 342–45. http://dx.doi.org/10.1100/tsw.2008.52.

Full text

Abstract:

Non-Hodgkin's lymphoma (NHL) represents about 3% of new cancer cases[1]. Bladder involvement has been found in approximately 3-13% of NHL patients when studied at postmortem[2]. Although accounting for only 0.2% of all primary bladder tumours, the majority of bladder lymphomas are B-cell lymphomas. T-cell lymphoma of the bladder is incredibly rare. We describe a case of anaplastic, T-cell lymphoma presenting with haematuria and loin pain, with unilateral upper tract obstruction.

APA, Harvard, Vancouver, ISO, and other styles

5

_, _. "Non-Hodgkin's Lymphoma Clinical Practice Guidelines." Journal of the National Comprehensive Cancer Network 4, no. 3 (2006): 258. http://dx.doi.org/10.6004/jnccn.2006.0025.

Full text

Abstract:

Non-Hodgkin's lymphomas (NHLs) may be classified on the basis of morphology, natural history, and immunophenotypic and molecular characteristics. These guidelines were developed for more common NHL histologic types, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, and for less common entities with unique natural histories and therapies, such as marginal zone lymphoma, mantle cell lymphoma, and highly aggressive lymphoma subtypes, including Burkitt's, and lymphoblastic lymphomas and AIDS-related B-cell lymphomas. Certain

APA, Harvard, Vancouver, ISO, and other styles

6

BURUIANA, Sanda, Maria ROBU, Victor TOMACINSCHII, Minodora MAZUR, and Lucia MAZUR-NICORICI. "Antiphospholipid Antibodies in Non-Hodgkin's Lymphoma." Documenta Haematologica - Revista Romana de Hematologie 3, no. 1 (2025): 19–27. https://doi.org/10.59854/dhrrh.2025.3.1.19.

Full text

Abstract:

Introduction: Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignant lymphoid tumors. Anticardiolipin (aCL), anti-β2 glycoprotein I (antiβ2GPI), lupus anticoagulant (LA) antibodies are found as NHL-associated acquired thrombophilic factors. Seropositivity of these antibodies in malignancies could remain asymptomatic. Despite these findings, the utility of routine testing for aCL, antiβ2GPI, LA antibodies in patients with NHL remains uncertain. Objective: This study aims to assess the prevalence of aCL, antiβ2GPI, LA antibodies in patients with nonHodgkin’s lymphomas depending on

APA, Harvard, Vancouver, ISO, and other styles

7

Diehl, V., and M. Reiser. "Follicular non-Hodgkin's lymphoma (NHL)." European Journal of Cancer 37 (April 2001): S132. http://dx.doi.org/10.1016/s0959-8049(01)80974-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Møller, M. B., F. d'Amore, and B. E. Christensen. "Testicular non-hodgkin's lymphoma (NHL)." European Journal of Cancer 30 (January 1994): S39. http://dx.doi.org/10.1016/0959-8049(94)90847-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Adouani, Ali, Jed Bouguila, Yassine Jeblaoui, et al. "B-Cell Lymphoma of the Mandible: A Case Report." Clinical medicine. Oncology 2 (January 2008): CMO.S366. http://dx.doi.org/10.4137/cmo.s366.

Full text

Abstract:

Introduction The mandible is an infrequent localisation of primary osseous non-Hodgkin's lymphomas. Few cases of mandibular non-Hodgkin's lymphomas (NHL) have been reported. Case Report A rare condition of primary malignant non-Hodgkin's lymphoma of the mandible in 53-year-old man, was reported at the Department of Maxillofacial and Plastic Surgery in Charles Nicolle Hospital (Tunis, Tunisia). Histologic and Immunohistochemical (IHC) examination Confirmed a B-Cell lymphoma. Discussion The purpose of this report is to describe this rare case of NHL of the mandible, explore the diagnosis and wor

APA, Harvard, Vancouver, ISO, and other styles

10

Macintyre, Elizabeth, Dennis Willerford, and Stephan W. Morris. "Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma." Hematology 2000, no. 1 (2000): 180–204. http://dx.doi.org/10.1182/asheducation.v2000.1.180.180.

Full text

Abstract:

Abstract The rapid increase in the incidence of the B cell non-Hodgkin's lymphomas (NHL) and improved understanding of the mechanisms involved in their development renders timely a review of the theoretical and practical aspects of molecular abnormalities in B cell NHL. In Section I, Dr. Macintyre addresses the practical aspects of the use of molecular techniques for the diagnosis and therapeutic management of patients with B cell NHL. While detection of clonal Ig rearrangements is widely used to distinguish reactive from malignant lymphoproliferative disorders, molecular informativity is vari

APA, Harvard, Vancouver, ISO, and other styles

11

Macintyre, Elizabeth, Dennis Willerford, and Stephan W. Morris. "Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma." Hematology 2000, no. 1 (2000): 180–204. http://dx.doi.org/10.1182/asheducation.v2000.1.180.20000180.

Full text

Abstract:

The rapid increase in the incidence of the B cell non-Hodgkin's lymphomas (NHL) and improved understanding of the mechanisms involved in their development renders timely a review of the theoretical and practical aspects of molecular abnormalities in B cell NHL. In Section I, Dr. Macintyre addresses the practical aspects of the use of molecular techniques for the diagnosis and therapeutic management of patients with B cell NHL. While detection of clonal Ig rearrangements is widely used to distinguish reactive from malignant lymphoproliferative disorders, molecular informativity is variable. The

APA, Harvard, Vancouver, ISO, and other styles

12

Magic, Zvonko, Tamara Novkovic, Bojana Cikota, Olga Tasic-Radic, Olivera Tarabar, and Dragana Stamatovic. "Genetic alterations in B-cell non-Hodgkin's lymphoma." Vojnosanitetski pregled 62, no. 2 (2005): 87–96. http://dx.doi.org/10.2298/vsp0502087m.

Full text

Abstract:

Background. Although the patients with diagnosed B-NHL are classified into the same disease stage on the basis of clinical, histopathological, and immunological parameters, they respond significantly different to the applied treatment. This points out the possibility that within the same group of lymphoma there are different diseases at molecular level. For that reason many studies deal with the detection of gene alterations in lymphomas to provide a better framework for diagnosis and treatment of these hematological malignancies. Aim. To define genetic alterations in the B-NHL with highest po

APA, Harvard, Vancouver, ISO, and other styles

13

Gospodarowicz, M. K., S. B. Sutcliffe, T. C. Brown, T. Chua, and R. S. Bush. "Patterns of disease in localized extranodal lymphomas." Journal of Clinical Oncology 5, no. 6 (1987): 875–80. http://dx.doi.org/10.1200/jco.1987.5.6.875.

Full text

Abstract:

The site of origin of lymphoid tissue is an important determinant of lymphocyte migration patterns. The association of gastrointestinal (GI) and Waldeyer's ring lymphoma and the unique lymphocyte migration pattern of gut-associated lymphoid tissue (GALT) have been previously described. To establish whether predictive clinical patterns of disease occur in localized Non-Hodgkin's lymphoma, survival and relapse patterns for 496 patients with stage I and II non-Hodgkin's lymphoma (NHL) treated with loco-regional irradiation (XRT) alone were examined. We identified 139 patients with GALT lymphoma (

APA, Harvard, Vancouver, ISO, and other styles

14

Goldberg, Jeffrey E., Augustine L. Moscatello, Reza Babapour, Douglas G. Finn, and Robert L. Pincus. "AIDS Related Non-Hodgkin's Lymphoma of the Paranasal Sinuses." American Journal of Rhinology 7, no. 1 (1993): 37–42. http://dx.doi.org/10.2500/105065893781976591.

Full text

Abstract:

Non-Hodgkin's Lymphoma (NHL) is an established early manifestation of Autoimmune Deficiency Syndrome (AIDS). It is estimated that up to 10% of HIV+ patients will eventually acquire NHL. These lymphomas differ from those occurring in the general population with regard to natural history, histopathology, location, and therapeutic response. A review of the literature demonstrates only two previously reported cases of NHL originating in the paranasal sinuses in AIDS patients. We present four cases of AIDS-related NHL of the paranasal sinuses diagnosed at our institutions. Clinical and histopatholo

APA, Harvard, Vancouver, ISO, and other styles

15

SAK, Adil, Sathya M, Vani D, and Nisarga MD. "Evaluation of epidemiological features and immunohistochemical profile of non-Hodgkin's lymphoma in a tertiary referral hospital." Journal of Medical and Scientific Research 13, no. 1 (2025): 12–19. https://doi.org/10.17727/jmsr.2024/13-3.

Full text

Abstract:

Background: Non-Hodgkin lymphoma (NHL) represents a diverse group of malignancies of lymphoid tissue due to clonal proliferation of lymphoid cells. India has a notable distribution of NHL, but its characterization and description are still insufficient. The objective of this study was to evaluate the epidemiological features and immunohistochemical profile of NHL in patients attending a tertiary referral hospital. Material and methods: This study is a descriptive analysis of cases patients diagnosed with NHL referred to the Department of Oncology at a tertiary referral hospital in South India.

APA, Harvard, Vancouver, ISO, and other styles

16

Ursan, M., and S. Buruiana. "IMMUNE ANEMIAS AND THROMBOCYTOPENIAS IN NON-HODGKIN'S LYMPHOMA." Deutsche internationale Zeitschrift für zeitgenössische Wissenschaft 49 (February 1, 2023): 24–26. https://doi.org/10.5281/zenodo.7594762.

Full text

Abstract:

Non-Hodgkin lymphomas (NHL) are the most common hematological malignancies, the incidence of which has shown a significant increase in rates over the year, worldwide, as well as in the Republic of Moldova. [1] The association of immune complications in patients with NHL is common, which can be appreciated shortly before or during the manifestation of the malignant lymphoma. [2, 3] On the basis of a database of 64 NHLs patients registered at the Oncological Institute, Chisinau, Republic of Moldova, a study was done to examine the clinical, and evolutionary particularities of immune anemias and

APA, Harvard, Vancouver, ISO, and other styles

17

Ford, RJ, NM Kouttab, CG Sahasrabuddhe, FM Davis, and SR Mehta. "Growth factor-mediated proliferation in B cell non-Hodgkin's lymphomas." Blood 65, no. 6 (1985): 1335–41. http://dx.doi.org/10.1182/blood.v65.6.1335.bloodjournal6561335.

Full text

Abstract:

Abstract The non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of human lymphoid tumors, primarily of B cell lineage, which appear to represent arrested stages in B lymphocyte differentiation. Control of cell proliferation is a fundamentally important but poorly understood area of study in these tumors. We have studied a representative group of B cell NHLs to assess their potential for growth factor-mediated proliferation in vitro. Our results show that purified monoclonal NHL B cells of the small cell (well-differentiated lymphocytic lymphoma, nodular poorly differentiated lymphocytic

APA, Harvard, Vancouver, ISO, and other styles

18

Rozenkov, Serhii, Sophia Kirilyuk, and Tetiana Negrich. "Neurolymphomatosis in Non-Hodgkin's Lymphoma." Ukrainian Scientific Medical Youth Journal 141, no. 3 (2023): 112–16. http://dx.doi.org/10.32345/usmyj.3(141).2023.112-116.

Full text

Abstract:

non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of hematopoietic puffins, with diphun B-velicocyclotinous lymphoma accounting for 25% of all NHLs and having the greatest midline to axis growth (Leeuwenуе et al., 2014). Of all NHLs, the central and peripheral nervous systems are most often affected in diphytic B-lycocytic lymphoma (Padala, & Kallam, 2022. Liu, & Barta, 2019). In NHL, infiltration of cranial and peripheral nerves can be detected - neurolymphomatosis (NL) emerges. NL is a very rare condition and occurs in about 0.2% of patients with NHL (Baehring, Damek, Martin,

APA, Harvard, Vancouver, ISO, and other styles

19

Vaccher, Emanuela, Domenico Errante, Marcello Tavio, et al. "HIV-RELATED NON-HODGKIN'S LYMPHOMA (NHL)." Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 14, no. 4 (1997): A41. http://dx.doi.org/10.1097/00042560-199704010-00141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Narmatha, M., J. Maheswari, and A. Premalatha. "Role of Immunohistochemistry and Its Correlation with Histopathological Diagnosis of Lymphomas." International Journal of Pharmaceutical and Clinical Research 15, no. 1 (2023): 751–61. https://doi.org/10.5281/zenodo.13143692.

Full text

Abstract:

<strong>Introduction:</strong> Currently, the diagnosis of lymphomas relies on immunophenotyping in addition to morphological features and relevant clinical data. According to WHO classification, lymphomas are categorized into Hodgkin’s and Non-Hodgkin’s lymphomas, further subclassified as T cell, B cell and NK cell types based on the cell lineage, stage of maturation and function. Appropriate selection of panel of antibody markers according to histopathological diagnosis is essential for definite and accurate diagnosis. <strong>Aims and</strong> <strong>Objectives:&

APA, Harvard, Vancouver, ISO, and other styles

21

Farquhar, D. L., G. K. Crompton, M. A. McIntyre, and R. C. F. Leonard. "Non-Hodgkin's Lymphoma of the Lung." Scottish Medical Journal 33, no. 2 (1988): 243–45. http://dx.doi.org/10.1177/003693308803300207.

Full text

Abstract:

Non-Hodgkin's lymphoma (NHL) commonly presents with extensive disease involving extranodal tissues. Involvement of the mediastinal and hilar lymph nodes, pleura and lung parenchyma are recognised complications although their incidence is uncertain. However pulmonary involvement is undoubtedly much less common than involvement at other extra nodal sites. Histologically proven NHL limited to the lung parenchyma, after full staging including computerised tomography and marrow trephines, is extremely rare. We report on two such cases and review the literature.

APA, Harvard, Vancouver, ISO, and other styles

22

Mikuls, Ted R., Justin O. Endo, Susan E. Puumala, et al. "Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis." Journal of Clinical Oncology 24, no. 10 (2006): 1597–602. http://dx.doi.org/10.1200/jco.2005.04.6227.

Full text

Abstract:

Purpose Although preliminary studies suggest that non-Hodgkin's lymphoma (NHL) complicating rheumatoid arthritis (RA) may be a clinically distinct entity compared with that occurring in the general population, studies examining the impact of antecedent RA on survival are limited. In this prospective study, we examined the association of RA with survival in patients with NHL. Patients and Methods Using two large lymphoma registries, we identified patients with evidence of RA preceding NHL. Survival in RA patients was compared with that of controls using proportional hazards regression, adjustin

APA, Harvard, Vancouver, ISO, and other styles

23

Mittal, Himanshu Kumar. "A Unique Case of Primary Extranodal Non-Hodgkin's Lymphoma of the Lacrimal Sac with Extension to Ipsilateral Nasal Cavity." An International Journal of Otorhinolaryngology Clinics 6, no. 3 (2014): 103–5. http://dx.doi.org/10.5005/jp-journals-10003-1167.

Full text

Abstract:

ABSTRACT The primary lacrimal sac involvement by malignant tumors is uncommon. The most commonly seen malignant tumors of the lacrimal sac are those of epithelial origin. Primary extranodal non-Hodgkin's lymphoma (PE-NHL) of the lacrimal sac is rare. We hereby present a rare case of primary non-Hodgkin's lymphoma (NHL) of the lacrimal sac with extension to the ipsilateral nasal cavity through the nasolacrimal duct. How to cite this article Mittal HK. A Unique Case of Primary Extranodal Non-Hodgkin's Lymphoma of the Lacrimal Sac with Extension to Ipsilateral Nasal Cavity. Int J Otorhinolaryngol

APA, Harvard, Vancouver, ISO, and other styles

24

Shaik, Mohammed Asif, Shefali Waghray, Sultan Mohammed Kaleem, Surekha Morrthy, and Naheeda Shaheen. "Primary Extranodal B-cell Lymphoma." International Journal of Experimental Dental Science 1, no. 1 (2012): 30–33. http://dx.doi.org/10.5005/jp-journals-10029-1007.

Full text

Abstract:

ABSTRACT Non-Hodgkin's lymphoma (NHL) constitutes a diverse group of lymphoid neoplasm that differs in manner of presentation, response to therapy and prognosis. They are less predictable and have a greater prediction to disseminate to extranodal sites. Their incidence has been increased over the last four decades and, head and neck is the second most common region for the extranodal lymphomas after that of gastrointestinal tract. Approximately 2.5% of malignant lymphomas arise in the oral and paraoral region. Generally, the oral manifestations of NHL are secondary to a more widespread involve

APA, Harvard, Vancouver, ISO, and other styles

25

Lanfermann, H., W. Heindel, J. Schaper, et al. "CT and MR imaging in primary cerebral Non-Hodgkin's lymphoma." Acta Radiologica 38, no. 2 (1997): 259–67. http://dx.doi.org/10.1080/02841859709172060.

Full text

Abstract:

Purpose: to determine the morphological appearance and topographical distribution of primary cerebral non-Hodgkin's lymphoma (NHL). Material and Methods: CT and MR examinations of 68 patients with primary cerebral NHL were analyzed. the NHLs were classified by the Kiel classification and im-munohistological data, as centroblastic (25), immunoblastic (24), lymphoblastic (5), Burkitt (1), non-subclassifiable type B (11), and T-cell lymphoma (2). Results: Centroblastic lymphomas tended to predominate in the parietal lobe (56.5%) and the corpus callosum (59.1%) while immunoblastic lymphomas were m

APA, Harvard, Vancouver, ISO, and other styles

26

Aggarwal, Deepti, Gunjan Srivastava, Ruchika Gupta, Leela Pant, Gopal Krishan, and Sompal Singh. "Angiogenesis in Non-Hodgkin's Lymphoma: An Intercategory Comparison of Microvessel Density." ISRN Hematology 2012 (March 27, 2012): 1–5. http://dx.doi.org/10.5402/2012/943089.

Full text

Abstract:

Background. This study was aimed at comparing angiogenesis, seen as microvessel density (MVD) in subtypes of non-Hodgkin’s lymphoma (NHL). Methods. In this study, 64 cases of NHL diagnosed over a three-year period were included along with 15 lymph node biopsies of reactive hyperplasia. NHLs were classified using REAL classification, and immunohistochemistry was performed for CD34 in all cases. CD34-stained sections were evaluated for “hot spots,” where MVD was assessed and expressed as per mm2. Appropriate statistical methods were applied. Results. There were 6 cases of well-differentiated lym

APA, Harvard, Vancouver, ISO, and other styles

27

Silver, R. T., D. C. Case, R. H. Wheeler, et al. "Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease." Journal of Clinical Oncology 9, no. 5 (1991): 754–61. http://dx.doi.org/10.1200/jco.1991.9.5.754.

Full text

Abstract:

In this phase II multicenter trial, the efficacy and safety of mitoxantrone (Novantrone; Lederle Laboratories, Wayne, NJ) were evaluated in the treatment of 206 patients with relapsed non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) previously treated with other agents. Sixty-nine percent of the patients had received prior therapy with doxorubicin. The patients received 14 mg/m2 of mitoxantrone every 3 weeks. Nineteen (12%) of the NHL patients and two (7%) of the HD patients had complete responses (CRs). The combined CR and partial response (PR) rates were 37% (60 of 163) for NHL patient

APA, Harvard, Vancouver, ISO, and other styles

28

Conlan, M. G., M. Bast, J. O. Armitage, and D. D. Weisenburger. "Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group." Journal of Clinical Oncology 8, no. 7 (1990): 1163–72. http://dx.doi.org/10.1200/jco.1990.8.7.1163.

Full text

Abstract:

Bone marrow specimens from 317 patients with non-Hodgkin's lymphoma (NHL) obtained at initial staging were evaluated for the presence of lymphoma or benign lymphoid aggregates. Thirty-two percent (102 patients) had lymphoma in their bone marrow, and 9% had benign lymphoid aggregates. Bone marrow lymphoma was present in 39% of low-grade, 36% of intermediate-grade, and 18% of high-grade lymphomas. The bone marrow was involved in 25% of patients with diffuse large-cell or immunoblastic NHL (ie, diffuse histiocytic lymphoma of Rappaport). Bone marrow involvement did not affect survival of patients

APA, Harvard, Vancouver, ISO, and other styles

29

Mahadevan, Daruka, and Richard I. Fisher. "Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma." Journal of Clinical Oncology 29, no. 14 (2011): 1876–84. http://dx.doi.org/10.1200/jco.2010.32.7171.

Full text

Abstract:

Application of advances in genomic and proteomic technologies has provided molecular insights into distinct types of aggressive B- and T-cell non-Hodgkin's lymphomas (NHLs). This has led to the validation of novel biomarkers of classification, risk-stratification, and druggable targets. The promise of novel treatments from genomic research has been slow to materialize because of the lack of a therapeutic signature for the distinct NHL subtypes. Patients with lymphoma with aggressive disease urgently require the development of novel therapies on the basis of investigation of dysregulated intrac

APA, Harvard, Vancouver, ISO, and other styles

30

Kars, A., G. Tekuzman, Ö. Özyilkan, et al. "Mine regimen in non-Hodgkin's lymphoma (NHL)." European Journal of Cancer 29 (January 1993): S176. http://dx.doi.org/10.1016/0959-8049(93)91600-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Van Schoor, J., G. Joos, and R. Pauwels. "Non-Hodgkin's lymphoma presenting as multiple cavitating pulmonary nodules." European Respiratory Journal 6, no. 8 (1993): 1229–31. http://dx.doi.org/10.1183/09031936.93.06081229.

Full text

Abstract:

Intrathoracic involvement is common in non-Hodgkin's lymphoma (NHL). We present the case of a young woman with a secondary pulmonary lymphoma (SPL) of the centroblastic subtype, with B-cell characteristics. The chest radiograph at presentation revealed an extremely rare pattern of multiple cavitating pulmonary nodules. The radiographic patterns of intrathoracic NHL are discussed.

APA, Harvard, Vancouver, ISO, and other styles

32

Fatiha, Md Ouakka, A. Elmoctar, K. Saoud, et al. "Primary Ovarian Burkitt’s lymphoma Mimicking a Gynecologic Tumor." Scholars International Journal of Obstetrics and Gynecology 6, no. 1 (2023): 29–33. http://dx.doi.org/10.36348/sijog.2023.v06i01.005.

Full text

Abstract:

Ovarian non-Hodgkin's lymphoma is an extremely rare tumor. It accounts for 1.5% of ovarian cancers and 0.5% of non-Hodgkin's lymphoma (NHL). It is most often a secondary location of a disseminated lymphomatous disease. We report on a patient managed in the department for this condition.

APA, Harvard, Vancouver, ISO, and other styles

33

Offit, K., NZ Parsa, G. Gaidano, et al. "6q deletions define distinct clinico-pathologic subsets of non- Hodgkin's lymphoma." Blood 82, no. 7 (1993): 2157–62. http://dx.doi.org/10.1182/blood.v82.7.2157.2157.

Full text

Abstract:

Abstract Commonly observed in lymphoid neoplasms, deletions of 6q have been correlated with histologic and clinical subsets of non-Hodgkin's lymphoma (NHL). Our recent analysis of loss of heterozygosity of 6q loci in NHL showed two regions of minimal molecular deletion (RMD), an RMD1 at 6q25–27 and an RMD2 at 6q21–23. To establish correlations between these RMDs and regions of minimal cytogenetic deletions (RCDs) on 6q, and to define associations between RCDs and clinico-pathologic features, we have analyzed chromosome 6 abnormalities in 459 consecutively ascertained, karyotypically abnormal c

APA, Harvard, Vancouver, ISO, and other styles

34

Offit, K., NZ Parsa, G. Gaidano, et al. "6q deletions define distinct clinico-pathologic subsets of non- Hodgkin's lymphoma." Blood 82, no. 7 (1993): 2157–62. http://dx.doi.org/10.1182/blood.v82.7.2157.bloodjournal8272157.

Full text

Abstract:

Commonly observed in lymphoid neoplasms, deletions of 6q have been correlated with histologic and clinical subsets of non-Hodgkin's lymphoma (NHL). Our recent analysis of loss of heterozygosity of 6q loci in NHL showed two regions of minimal molecular deletion (RMD), an RMD1 at 6q25–27 and an RMD2 at 6q21–23. To establish correlations between these RMDs and regions of minimal cytogenetic deletions (RCDs) on 6q, and to define associations between RCDs and clinico-pathologic features, we have analyzed chromosome 6 abnormalities in 459 consecutively ascertained, karyotypically abnormal cases of N

APA, Harvard, Vancouver, ISO, and other styles

35

Stauder, R., W. Eisterer, J. Thaler, and U. Gunthert. "CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor." Blood 85, no. 10 (1995): 2885–99. http://dx.doi.org/10.1182/blood.v85.10.2885.bloodjournal85102885.

Full text

Abstract:

Isoforms of the transmembrane glycoprotein CD44, generated by alternative RNA splicing, have been correlated to tumor dissemination. For evaluation of the potential role of CD44 variant isoforms in non- Hodgkin's lymphoma (NHL), the presence of CD44 isoforms was analyzed in a large panel of reactive and neoplastic lymphoid tissues by immunohistochemical staining, as well as detection of CD44 variant RNAs by the reverse transcriptase-polymerase chain reaction. Whereas the CD44 standard or hematopoietic isoform (CD44s), devoid of the variant regions, was expressed in all leukocyte subpopulations

APA, Harvard, Vancouver, ISO, and other styles

36

Arnogiannaki, Niki, Charalampos Grigoriadis, Dimitrios Zygouris, Georgios Androutsopoulos, Grigorios Derdelis, and Emmanouil Terzakis. "Primary ovarian non-Hodgkin's lymphoma." Eur J Gynaecol Oncol 32, no. 4 (2011): 441–42. https://doi.org/10.5281/zenodo.6059294.

Full text

Abstract:

Background: Primary ovarian non Hodgkin’s lymphoma (PONHL) is a very rare disease. We present a case of PONHL and review the literature. Case: The patient, a 24-year-old nulliparous Greek woman, presented with a complaint of abdominal pain. She underwent left salpingo-oophorectomy, multiple biopsies from the right ovary, total omentectomy, pelvic and paraortic lymphadenectomy, appendectomy and curettage. The histopathology revealed diffuse large B-cell non-Hodgkin’s lymphoma of the left ovary. She underwent postoperative chemotherapy. She remains well without evidence of disease, 1

APA, Harvard, Vancouver, ISO, and other styles

37

Stagnaro, Emanuele, Rosario Tumino, Stefano Parodi, et al. "Non-Hodgkin's Lymphoma and Type of Tobacco Smoke." Cancer Epidemiology, Biomarkers & Prevention 13, no. 3 (2004): 431–37. http://dx.doi.org/10.1158/1055-9965.431.13.3.

Full text

Abstract:

Abstract Background: In recent decades, the incidence of non-Hodgkin's lymphoma (NHL) has increased in all industrialized countries. Tobacco smoke contains several recognized or putative carcinogenic compounds that differ in concentration depending on which of the two main types, blond or black, is consumed. This investigation sought to evaluate the association between NHL and type of tobacco smoked (blond, black, or mixed), focusing on the Working Formulation (WF) subgroups. Methods: Reanalysis of Italian data from a recent multicenter population-based case-control study. The 1450 cases of NH

APA, Harvard, Vancouver, ISO, and other styles

38

Lo Coco, F., BH Ye, F. Lista, et al. "Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma." Blood 83, no. 7 (1994): 1757–59. http://dx.doi.org/10.1182/blood.v83.7.1757.1757.

Full text

Abstract:

Abstract The pathogenesis of non-Hodgkin's lymphoma (NHL) with a large cell component (DLLC, including diffuse large cell, DLCL; diffuse mixed cell, MX-D; and immunoblastic, IMB) is unknown. A novel candidate proto- oncogene, BCL6, that is involved in chromosome band 3q27 aberrations in NHL has been recently identified. We have investigated the incidence and disease-specificity of BCL6 rearrangements in a large panel of lymphoid tumors, including acute and chronic lymphoid leukemias (96 cases), various NHL types (125 cases), and multiple myelomas (23 cases). BCL6 rearrangements were found in 1

APA, Harvard, Vancouver, ISO, and other styles

39

Lo Coco, F., BH Ye, F. Lista, et al. "Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma." Blood 83, no. 7 (1994): 1757–59. http://dx.doi.org/10.1182/blood.v83.7.1757.bloodjournal8371757.

Full text

Abstract:

The pathogenesis of non-Hodgkin's lymphoma (NHL) with a large cell component (DLLC, including diffuse large cell, DLCL; diffuse mixed cell, MX-D; and immunoblastic, IMB) is unknown. A novel candidate proto- oncogene, BCL6, that is involved in chromosome band 3q27 aberrations in NHL has been recently identified. We have investigated the incidence and disease-specificity of BCL6 rearrangements in a large panel of lymphoid tumors, including acute and chronic lymphoid leukemias (96 cases), various NHL types (125 cases), and multiple myelomas (23 cases). BCL6 rearrangements were found in 16/45 (35.

APA, Harvard, Vancouver, ISO, and other styles

40

Rodriguez, Laura, Mohammed Zolaly, Sheila Weitzman, Ahmed Naqvi, Angela Punnet, and Oussama Abla. "Outcome of Young Children with Non-Hodgkin's Lymphoma." Blood 120, no. 21 (2012): 5106. http://dx.doi.org/10.1182/blood.v120.21.5106.5106.

Full text

Abstract:

Abstract Abstract 5106 Background: The incidence and biology of non-Hodgkin's lymphoma (NHL) vary according to age, and the outcome differs amongst children being less favorable in infants and adolescents. Objectives: To analyze the outcome and toxicity patterns of young children with NHL comparing patients aged < 10 years to those 10–18 years of age. Methods: A retrospective review of children ≤ 18 years of age diagnosed with NHL over a period of 13 years. Patients were treated according to different protocols and treatment subgroups included: Burkitt lymphoma (BL), diffuse large B-cell ly

APA, Harvard, Vancouver, ISO, and other styles

41

van Leeuwen, F. E., R. Somers, B. G. Taal, et al. "Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease." Journal of Clinical Oncology 7, no. 8 (1989): 1046–58. http://dx.doi.org/10.1200/jco.1989.7.8.1046.

Full text

Abstract:

The risk of second cancers (SCs) was assessed in 744 patients with Hodgkin's disease (HD) admitted to The Netherlands Cancer Institute from 1966 to 1983. Sixty-nine SCs were observed one month or more after start of first treatment. These included 14 cases of lung cancer, nine cases of non-Hodgkin's lymphoma (NHL), 16 cases of leukemia, and six cases of the myelodysplastic syndrome (MDS). The median interval between the diagnosis of HD and that of second lung cancer, NHL, and leukemia was 8.1, 13.3, and 5.7 years, respectively. The overall relative risks (RR) (observed/expected [O/E] ratios) o

APA, Harvard, Vancouver, ISO, and other styles

42

Anderson, Lesley A., Ruth M. Pfeiffer, Joshua S. Rapkin, et al. "Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma." Journal of Clinical Oncology 26, no. 30 (2008): 4958–65. http://dx.doi.org/10.1200/jco.2007.14.6571.

Full text

Abstract:

Purpose Genetic factors are important in the etiology and pathogenesis of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). Only a few small studies have assessed clinical characteristics and prognosis for familial patients, with inconsistent findings. Methods Using population-based registries from Sweden and Denmark, 7,749 patients with CLL, 7,476 patients with HL, and 25,801 patients with NHL with linkable first-degree relatives were identified. Kaplan-Meier curves were constructed to compare survival in patients with lymphoma with and without a f

APA, Harvard, Vancouver, ISO, and other styles

43

Mohammed, Sharique, Gupta Sunil, Laxmi Gupta Vijay, and Sharma Neha. "Burden of Organochlorine Pesticides and Their Association with Occurrence of Lymphomas." International Journal of Pharmaceutical and Clinical Research 15, no. 6 (2023): 713–18. https://doi.org/10.5281/zenodo.12193292.

Full text

Abstract:

<strong>Background:</strong> Unheeding use of these chemical pesticides in farming, animal husbandry, factories and public health operations has emerged as a long-term irreversible environmental damage, throughout the globe. Apart from causing acute and chronic toxicity, organochlorine pesticides are also known to increase the risk of carcinogenesis by acting as carcinogens themselves and also by suppressing the immune system which has the ability to destroy the process of carcinogenesis in the body. <strong>Material & Methods:</strong> A total of 135 study subjects were rec

APA, Harvard, Vancouver, ISO, and other styles

44

Schouten, HC, PJ Bierman, WP Vaughan, et al. "Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation." Blood 74, no. 7 (1989): 2579–84. http://dx.doi.org/10.1182/blood.v74.7.2579.2579.

Full text

Abstract:

Abstract Patients with disseminated follicular non-Hodgkin's lymphoma (NHL) are only occasionally cured with standard chemotherapy regimens. Although most of these tumors are initially responsive to chemotherapy, in 40% to 70% of patients the lymphoma will eventually transform to an NHL of higher grade malignancy and a poorer prognosis. We treated 18 patients having an original diagnosis of follicular NHL with high-dose therapy and autologous bone marrow transplantation. The lymphomas of 10 of the patients had already undergone histologic transformation and eight still had a follicular histolo

APA, Harvard, Vancouver, ISO, and other styles

45

Schouten, HC, PJ Bierman, WP Vaughan, et al. "Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation." Blood 74, no. 7 (1989): 2579–84. http://dx.doi.org/10.1182/blood.v74.7.2579.bloodjournal7472579.

Full text

Abstract:

Patients with disseminated follicular non-Hodgkin's lymphoma (NHL) are only occasionally cured with standard chemotherapy regimens. Although most of these tumors are initially responsive to chemotherapy, in 40% to 70% of patients the lymphoma will eventually transform to an NHL of higher grade malignancy and a poorer prognosis. We treated 18 patients having an original diagnosis of follicular NHL with high-dose therapy and autologous bone marrow transplantation. The lymphomas of 10 of the patients had already undergone histologic transformation and eight still had a follicular histologic patte

APA, Harvard, Vancouver, ISO, and other styles

46

Gisselbrecht, C., D. Maraninchi, JL Pico, et al. "Interleukin-2 treatment in lymphoma: a phase II multicenter study [see comments]." Blood 83, no. 8 (1994): 2081–85. http://dx.doi.org/10.1182/blood.v83.8.2081.2081.

Full text

Abstract:

Abstract A phase II study was undertaken to assess whether continuous infusion of high-dose recombinant interleukin-2 (rIL-2) alone was active against different histologic subtypes of heavily pretreated lymphoma. Sixty one lymphomas were included in the study. rIL-2 (Roussel UCLAF, Romainville, France) was administered by continuous infusion at 20 x 10(6) IU/m2 for three cycles of 5 days, 4 days, and 3 days, during the first week, third week, and fifth week, respectively. Twenty-four low- grade non-Hodgkin's lymphomas (NHL) were resistant to an anthracycline- containing regimen. Twenty-three i

APA, Harvard, Vancouver, ISO, and other styles

47

Gisselbrecht, C., D. Maraninchi, JL Pico, et al. "Interleukin-2 treatment in lymphoma: a phase II multicenter study [see comments]." Blood 83, no. 8 (1994): 2081–85. http://dx.doi.org/10.1182/blood.v83.8.2081.bloodjournal8382081.

Full text

Abstract:

A phase II study was undertaken to assess whether continuous infusion of high-dose recombinant interleukin-2 (rIL-2) alone was active against different histologic subtypes of heavily pretreated lymphoma. Sixty one lymphomas were included in the study. rIL-2 (Roussel UCLAF, Romainville, France) was administered by continuous infusion at 20 x 10(6) IU/m2 for three cycles of 5 days, 4 days, and 3 days, during the first week, third week, and fifth week, respectively. Twenty-four low- grade non-Hodgkin's lymphomas (NHL) were resistant to an anthracycline- containing regimen. Twenty-three intermedia

APA, Harvard, Vancouver, ISO, and other styles

48

Ragni, MV, SH Belle, RA Jaffe, et al. "Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia." Blood 81, no. 7 (1993): 1889–97. http://dx.doi.org/10.1182/blood.v81.7.1889.1889.

Full text

Abstract:

Abstract Non-Hodgkin's lymphoma (NHL) is the most common human immunodeficiency virus (HIV)-associated malignancy in hemophiliacs. We studied the incidence and clinicopathologic features of NHL in 3,041 hemophiliacs followed at 18 US Hemophilia Centers between 1978 and 1989. Of the 1,295 (56.6%) who were HIV(+), 253 (19.5%) developed acquired immunodeficiency syndrome (AIDS), of whom 14 (5.5%) developed NHL. Three NHL occurred in HIV(-) hemophiliacs, for a 36.5-fold greater risk in HIV(+) than HIV(-) hemophiliacs (P < .001). The NHL incidence rate was 29-fold greater than in the US populati

APA, Harvard, Vancouver, ISO, and other styles

49

Ragni, MV, SH Belle, RA Jaffe, et al. "Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia." Blood 81, no. 7 (1993): 1889–97. http://dx.doi.org/10.1182/blood.v81.7.1889.bloodjournal8171889.

Full text

Abstract:

Non-Hodgkin's lymphoma (NHL) is the most common human immunodeficiency virus (HIV)-associated malignancy in hemophiliacs. We studied the incidence and clinicopathologic features of NHL in 3,041 hemophiliacs followed at 18 US Hemophilia Centers between 1978 and 1989. Of the 1,295 (56.6%) who were HIV(+), 253 (19.5%) developed acquired immunodeficiency syndrome (AIDS), of whom 14 (5.5%) developed NHL. Three NHL occurred in HIV(-) hemophiliacs, for a 36.5-fold greater risk in HIV(+) than HIV(-) hemophiliacs (P < .001). The NHL incidence rate was 29-fold greater than in the US population by Sur

APA, Harvard, Vancouver, ISO, and other styles

50

Sheniz, Yu, Sh Bozhidara, M. Ilina, and G. Liana. "PROGNOSTIC SIGNIFICANCE OF PLATELET- NEUTROPHIL COMPLEXES IN NON-HODGKIN’S LYMPHOMA PATIENTS." ASJ 1, no. 54 (2021): 14–17. http://dx.doi.org/10.31618/asj.2707-9864.2021.1.54.127.

Full text

Abstract:

Abstract. Non-Hodgkin's lymphomas (NHL) are a group of lymphoproliferative diseases with a heterogeneous spectrum of clinical, morphological, and immunophenotypic characteristics. Non-Hodgkin’s lymphoma is characterized by abnormal proliferation or accumulation of B or T lymphocytes. Circulating neutrophils and platelets have a proven role in both the pathogenesis of inflammatory processes and thrombosis and in the processes of tumorigenesis.The formation of complexes between neutrophils and circulating platelets (PNC) is a fundamental mechanism that is known but poorly studied in non-Hodgkin'

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!